- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
GAITHERSBURG, Md., Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: | |
Date: | February 28, 2023 |
Time: | 4:30 p.m. U.S. Eastern Standard Time (EST) |
Dial-in number: | (833) 974-2381 (Domestic) or (412) 317-5774 (International) |
Webcast: |
- Participants will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details: | |
Date: | Available starting at 7:30 p.m. EST, February 28, 2023 until 11:59 p.m. U.S. EST, March 7, 2023 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 1137418 |
Webcast: | ir.novavax.com/events, until May 28, 2023 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
CONTACTS
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Ali Chartan
240-720-7804
[email protected]
SOURCE Novavax, Inc.
